Osteosarcoma Clinical Trials

52 recruiting

Osteosarcoma Trials at a Glance

64 actively recruiting trials for osteosarcoma are listed on ClinicalTrialsFinder across 6 cities in 17 countries. The largest study group is Phase 1 with 28 trials, with the heaviest enrollment activity in Atlanta, Boston, and St Louis. Lead sponsors running osteosarcoma studies include Peking University People's Hospital, St. Jude Children's Research Hospital, and Children's Oncology Group.

Browse osteosarcoma trials by phase

Treatments under study

About Osteosarcoma Clinical Trials

Looking for clinical trials for Osteosarcoma? There are currently 52 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Osteosarcoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Osteosarcoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 64 trials

Recruiting
Phase 2Phase 3

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Metastatic OsteosarcomaHigh Grade OsteosarcomaLocalized Osteosarcoma+1 more
National Cancer Institute (NCI)1,122 enrolled190 locationsNCT05691478
Recruiting
Phase 1Phase 2

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

Relapsed / Refractory Osteosarcoma
Lantheus Medical Imaging55 enrolled2 locationsNCT07357519
Recruiting
Phase 1Phase 2

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

AngiosarcomaLiposarcomaAdipocytic Neoplasm+6 more
St. Jude Children's Research Hospital139 enrolled6 locationsNCT06239272
Recruiting

Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas

OsteosarcomaChondrosarcomaBone Sarcoma+3 more
Memorial Sloan Kettering Cancer Center300 enrolled5 locationsNCT03442465
Recruiting
Phase 2

Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study

Metastatic OsteosarcomaRecurrent OsteosarcomaRefractory Osteosarcoma+2 more
M.D. Anderson Cancer Center40 enrolled2 locationsNCT05019703
Recruiting
Not Applicable

Musculoskeletal Cancers Remote Monitoring and Care

OsteosarcomaMetastatic Bone Disease
Case Comprehensive Cancer Center60 enrolled1 locationNCT07129226
Recruiting
Phase 2

Agnostic Therapy in Rare Solid Tumors

Cancer of Unknown PrimarySoft Tissue SarcomaCholangiocarcinoma+38 more
Instituto do Cancer do Estado de São Paulo28 enrolled8 locationsNCT06638931
Recruiting
Phase 1

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Soft Tissue SarcomaMelanomaCarcinoma+13 more
St. Jude Children's Research Hospital48 enrolled1 locationNCT04897321
Recruiting
Phase 1Phase 2

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Recurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRecurrent Solid Tumor+19 more
St. Jude Children's Research Hospital90 enrolled10 locationsNCT04901702
Recruiting
Phase 1Phase 2

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

OsteosarcomaEwing SarcomaNeuroblastoma+4 more
Milton S. Hershey Medical Center289 enrolled10 locationsNCT06465199
Recruiting
Phase 1Phase 2

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

OsteosarcomaEwing SarcomaNeuroblastoma+2 more
Milton S. Hershey Medical Center104 enrolled21 locationsNCT06541262
Recruiting
Phase 1

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

OsteosarcomaNeuroblastoma
UNC Lineberger Comprehensive Cancer Center18 enrolled2 locationsNCT03721068
Recruiting

Observational Study in Localized Osteosarcoma

Localized Osteosarcoma
Italian Sarcoma Group120 enrolled16 locationsNCT04890067
Recruiting
Phase 1Phase 2

Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma

OsteosarcomaOsteosarcoma Metastatic
Peking University People's Hospital56 enrolled1 locationNCT07479732
Recruiting

Upfront Surgical Resection for Osteosarcoma

Osteosarcoma
Montefiore Medical Center10 enrolled1 locationNCT06384404
Recruiting
Phase 2

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

MetastasisOsteosarcoma
Memorial Sloan Kettering Cancer Center45 enrolled7 locationsNCT07477457
Recruiting
Phase 1Phase 2

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

OsteosarcomaEwing SarcomaNeuroblastoma+10 more
University of Florida27 enrolled1 locationNCT06625190
Recruiting
Phase 1Phase 2

Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

Advanced Renal Cell CarcinomaAdvanced MesotheliomaAdvanced Osteosarcoma
M.D. Anderson Cancer Center50 enrolled1 locationNCT05703854
Recruiting
Phase 1

Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma

OsteosarcomaPulmonary Recurrence of Osteosarcoma
Emory University12 enrolled1 locationNCT06492954
Recruiting
Phase 1

Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

Refractory OsteosarcomaOsteosarcoma in ChildrenOsteosarcoma Recurrent+1 more
Emory University24 enrolled1 locationNCT07144254